ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida.
Adolescent
Adult
Aged
COVID-19
/ mortality
Comorbidity
Delivery of Health Care
Extracorporeal Membrane Oxygenation
Female
Florida
Hospital Mortality
Humans
Intensive Care Units
Length of Stay
Male
Middle Aged
Respiration, Artificial
Retrospective Studies
SARS-CoV-2
Severity of Illness Index
Young Adult
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
27
07
2020
accepted:
09
03
2021
entrez:
25
3
2021
pubmed:
26
3
2021
medline:
14
4
2021
Statut:
epublish
Résumé
Observational studies have consistently described poor clinical outcomes and increased ICU mortality in patients with severe coronavirus disease 2019 (COVID-19) who require mechanical ventilation (MV). Our study describes the clinical characteristics and outcomes of patients with severe COVID-19 admitted to ICU in the largest health care system in the state of Florida, United States. Retrospective cohort study of patients admitted to ICU due to severe COVID-19 in AdventHealth health system in Orlando, Florida from March 11th until May 18th, 2020. Patients were characterized based on demographics, baseline comorbidities, severity of illness, medical management including experimental therapies, laboratory markers and ventilator parameters. Major clinical outcomes analyzed at the end of the study period were: hospital and ICU length of stay, MV-related mortality and overall hospital mortality of ICU patients. Out of total of 1283 patients with COVID-19, 131 (10.2%) met criteria for ICU admission (median age: 61 years [interquartile range (IQR), 49.5-71.5]; 35.1% female). Common comorbidities were hypertension (84; 64.1%), and diabetes (54; 41.2%). Of the 131 ICU patients, 109 (83.2%) required MV and 9 (6.9%) received ECMO. Lower positive end expiratory pressure (PEEP) were observed in survivors [9.2 (7.7-10.4)] vs non-survivors [10 (9.1-12.9] p = 0.004]. Compared to non-survivors, survivors had a longer MV length of stay (LOS) [14 (IQR 8-22) vs 8.5 (IQR 5-10.8) p< 0.001], Hospital LOS [21 (IQR 13-31) vs 10 (7-1) p< 0.001] and ICU LOS [14 (IQR 7-24) vs 9.5 (IQR 6-11), p < 0.001]. The overall hospital mortality and MV-related mortality were 19.8% and 23.8% respectively. After exclusion of hospitalized patients, the hospital and MV-related mortality rates were 21.6% and 26.5% respectively. Our study demonstrates an important improvement in mortality of patients with severe COVID-19 who required ICU admission and MV in comparison to previous observational reports and emphasizes the importance of standard of care measures in the management of COVID-19.
Sections du résumé
BACKGROUND
Observational studies have consistently described poor clinical outcomes and increased ICU mortality in patients with severe coronavirus disease 2019 (COVID-19) who require mechanical ventilation (MV). Our study describes the clinical characteristics and outcomes of patients with severe COVID-19 admitted to ICU in the largest health care system in the state of Florida, United States.
METHODS
Retrospective cohort study of patients admitted to ICU due to severe COVID-19 in AdventHealth health system in Orlando, Florida from March 11th until May 18th, 2020. Patients were characterized based on demographics, baseline comorbidities, severity of illness, medical management including experimental therapies, laboratory markers and ventilator parameters. Major clinical outcomes analyzed at the end of the study period were: hospital and ICU length of stay, MV-related mortality and overall hospital mortality of ICU patients.
RESULTS
Out of total of 1283 patients with COVID-19, 131 (10.2%) met criteria for ICU admission (median age: 61 years [interquartile range (IQR), 49.5-71.5]; 35.1% female). Common comorbidities were hypertension (84; 64.1%), and diabetes (54; 41.2%). Of the 131 ICU patients, 109 (83.2%) required MV and 9 (6.9%) received ECMO. Lower positive end expiratory pressure (PEEP) were observed in survivors [9.2 (7.7-10.4)] vs non-survivors [10 (9.1-12.9] p = 0.004]. Compared to non-survivors, survivors had a longer MV length of stay (LOS) [14 (IQR 8-22) vs 8.5 (IQR 5-10.8) p< 0.001], Hospital LOS [21 (IQR 13-31) vs 10 (7-1) p< 0.001] and ICU LOS [14 (IQR 7-24) vs 9.5 (IQR 6-11), p < 0.001]. The overall hospital mortality and MV-related mortality were 19.8% and 23.8% respectively. After exclusion of hospitalized patients, the hospital and MV-related mortality rates were 21.6% and 26.5% respectively.
CONCLUSIONS
Our study demonstrates an important improvement in mortality of patients with severe COVID-19 who required ICU admission and MV in comparison to previous observational reports and emphasizes the importance of standard of care measures in the management of COVID-19.
Identifiants
pubmed: 33765049
doi: 10.1371/journal.pone.0249038
pii: PONE-D-20-23392
pmc: PMC7993561
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0249038Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
N Engl J Med. 2013 Jun 6;368(23):2159-68
pubmed: 23688302
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Respir Care. 2017 Jan;62(1):113-122
pubmed: 27803355
Mod Pathol. 2020 Nov;33(11):2156-2168
pubmed: 32879413
Intensive Care Med. 2018 Jun;44(6):925-928
pubmed: 29675566
Chest. 2020 Jul;158(1):e9-e13
pubmed: 32243945
Lancet Infect Dis. 2020 Apr;20(4):398-400
pubmed: 32113510
Med Mal Infect. 2020 Jun;50(4):384
pubmed: 32240719
JAMA. 2020 May 19;323(19):1891-1892
pubmed: 32293639
BMJ. 2020 May 22;369:m1923
pubmed: 32444358
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
J Med Virol. 2020 Nov;92(11):2516-2522
pubmed: 32436994
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
JAMA. 2020 Jun 2;323(21):2195-2198
pubmed: 32329797
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1430-1434
pubmed: 32267160
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Lancet Respir Med. 2020 Apr;8(4):e24
pubmed: 32178774
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):465-471
pubmed: 32298250
JAMA. 2020 Apr 28;323(16):1612-1614
pubmed: 32191259
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Crit Care. 2020 Jun 4;24(1):285
pubmed: 32498689
Sci Total Environ. 2020 Jul 1;724:138226
pubmed: 32408453
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619887437
pubmed: 31775524
Anesth Analg. 2020 Aug;131(2):e114-e115
pubmed: 32366771
JAMA. 2017 Oct 10;318(14):1335-1345
pubmed: 28973363
Lancet Respir Med. 2020 Mar;8(3):267-276
pubmed: 32043986
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Crit Care Med. 2020 Sep;48(9):e783-e790
pubmed: 32459672
Ann Intern Med. 2017 Sep 19;167(6):424-431
pubmed: 28655034
JAMA. 2020 Jun 9;323(22):2329-2330
pubmed: 32329799
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Trials. 2016 Jul 22;17:342
pubmed: 27449641
J Crit Care. 2020 Aug;58:27-28
pubmed: 32279018